Joint Symposium
ESTRO-EFOMP: Multi-disciplinary working in Radiotherapy ................................................................. Abs. 132-135

Symposium
Younger people and radiotherapy ........................................................................................................... Abs. 136-138

Poster Viewing
Poster viewing 3: Brachytherapy ........................................................................................................... Abs. 139-147

Multidisciplinary Tumour Board
Soft tissue sarcomas

Proffered Papers
RB 2: How to exploit immunogenic cell death mechanisms in radiotherapy ........................................ Abs. 151-157
CL 3: Proffered papers: Prostate and Bladder ......................................................................................... Abs. 158-164
CL 4: proffered papers: CNS and Paediatrics ........................................................................................ Abs. 165-171
BT 2: Cervix brachytherapy .................................................................................................................... Abs. 172-178
PH 3: Proffered paper: New developments in automated treatment planning ...................................... Abs. 179-185
PH 4: Proffered paper: New technologies .............................................................................................. Abs. 186-192
RTT 2: A patient centered approach to follow up ................................................................................ Abs. 193-199

Poster Viewing
Poster viewing 4: Head-Neck and Lung .................................................................................................... Abs. 200-208

Award Lecture
Honorary Members award lectures ................................................................................................................ Abs. 209-211

28 APRIL 2019

Teaching Lecture
Re-irradiation for breast cancer ................................................................................................................ Abs. 212
Extracellular vesicles; are we there yet? ................................................................................................ Abs. 213
Update on the management of SCLC ......................................................................................................... Abs. 214
How to combine checkpoint inhibitors with radiotherapy? ................................................................. Abs. 215
How does brachytherapy fit in the modern management of penile cancer? ........................................ Abs. 216
Detector specific output correction factors: How to use them in practice ........................................ Abs. 217
Uncertainties in Radiomics ..................................................................................................................... Abs. 218
New technology and modalities in Radiotherapy - What can the ESTRO School offer? ................ Abs. 219
Precision medicine and systems biology - transforming cancer research in the 21st century .......... Abs. 220

Symposium
Balancing the risks and benefits of re-irradiation ................................................................................ Abs. 221-224
Circulating biomarkers for patient stratification and treatment monitoring ........................................ Abs. 225-228

Debate
This house believes that Proton-beam be used routinely in the treatment of lung cancer

Symposium
Radiation–drug combinations on the 2019 horizon ........................................................................... Abs. 229-232
Inverse planning in brachytherapy - A one click solution? ................................................................. Abs. 233-235
Reference and non-reference dosimetry - CoPs and beyond .............................................................. Abs. 236-239
New advances in image reconstruction in CBCT ............................................................................... Abs. 240-242
New technology and modalities .......................................................................................................... Abs. 243-245
Combining research and clinical/ professional training/ practice .................................................... Abs. 246-250

Poster Viewing
Poster viewing 5: Health Services Research and Health-Related Quality of Life ........................ Abs. 251-259
Networking session
Speed Dating with Quiz

Joint Symposium
ESTRO-JASTRO: Clinical trials for particle therapy: which ones to run and how? ................................................................. Abs. 260-263

Proffered Papers
RB 3: Tumour sensitization ........................................ Abs. 264-268
CL 5: Proffered papers: Randomised Clinical Trials ................................................................. Abs. 269-274
CL 6: Proffered papers Radiation and Targeted Agents ................................................................. Abs. 275-281
BT 3: Prostate HDR brachytherapy ........................................ Abs. 282-288
PH 5: Proffered paper: Innovations in dosimetry and dose measurements ........................................ Abs. 289-295
PH 6: Proffered paper: X-ray guided tumour tracking ................................................................. Abs. 296-302
RTT 3: Impact of variations on treatment planning ................................................................. Abs. 303-307

Poster Viewing
Poster viewing 6: Radiobiological modelling and quantitative imaging ................................................ Abs. 308-316

Proffered Papers
BT 4: Breast and Skin brachytherapy ................................................................. Abs. 317-323

Presidential Symposium
Presidential symposium ................................................................. Abs. 324

Award Lecture
Claudius Regaud Award Lecture ................................................................. Abs. 325

Symposium
How to prevent burnout? ................................................................. Abs. 326-330
The microbiome, inflammation and radiotherapy response ........................................ Abs. 332-334
Reducing the normal tissue effects of RT ................................................................. Abs. 335-338
Radiotherapy in the era of the Silver Tsunami ................................................................. Abs. 339-342

Debate
This house believes that margin reduction is the key to improved outcome
Which is the best brachytherapy technique to deliver partial breast irradiation? Pitfalls, results and current recommendations ...... Abs. 343-346

Symposium
Big data – big problems? ................................................................. Abs. 347-349
From grid therapy to microbeam radiotherapy ................................................................. Abs. 350-353
Focus on the lung ................................................................. Abs. 354-356
Stronger together - news and projects in the young national societies ........................................ Abs. 357-360

Poster Viewing
Poster viewing 7: CNS, Paediatrics, Haematology and Gynaecology ................................................ Abs. 361-369

Multidisciplinary Tumour Board
Prostate cancer

Networking session
Quiz and Young networking cocktail

Joint Symposium
ESTRO-ASTRO: Translating discovery to cure ................................................................. Abs. 370-373

Proffered Papers
RB 4: Normal tissue effects of radiotherapy ................................................................. Abs. 374-379
CL 7: Proffered papers: GI ................................................................. Abs. 380-386
CL 8: Proffered papers: Head and Neck ................................................................. Abs. 387-393
BT 5: Optimising dose distribution ................................................................. Abs. 394-400
PH 7: Proffered paper: Outcome modelling ................................................................. Abs. 401-407
PH 8: Proffered paper: Handling intra-fraction motion in MR guided RT .................... Abs. 408-414
RTT 4: Reducing uncertainties in volume definition .................................................. Abs. 415-421

Poster Viewing
Poster viewing 8: TP Developments ........................................................................... Abs. 422-430

Proffered Papers
BT 6: Innovative and uncommon indications ............................................................... Abs. 431-437

Award Lecture
Jens Overgaard Legacy Award Lecture
Honorary Physicist Award Lecture ................................................................................. Abs. 438

29 APRIL 2019

Teaching Lecture
Extreme hypofractionation in the treatment of localized prostate cancer ................ Abs. 439
Radio-immunotherapy: challenges and opportunities ................................................ Abs. 440
Tumor metabolism and radiation response ................................................................. Abs. 441
Radiomic machine-learning to predict radiotherapy outcome .................................... Abs. 442
Importance of volumetric staging and biological dose inhomogeneity in IMRT ...... Abs. 443
In-vivo dosimetry: Possibilities and Pitfalls ............................................................... Abs. 444
The vital role of physicists in clinical trials: from design to data analysis ................. Abs. 445
New developments in the treatment of brain metastases: better prognostic tools, improved outcomes ................................................................. Abs. 446

Symposium
Radiotherapy in bladder cancer: Standard of care and future perspectives ................ Abs. 447-450

Joint Symposium
ESTRO-EACR: Radio-immunotherapy: from concept to clinical practice ............... Abs. 451-454

Symposium
Tumor Metabolism and Radiotherapy .......................................................................... Abs. 455-458

Joint Symposium
ESTRO-ESR: Current status and future challenges in MR-integrated radiotherapy ........ Abs. 459-462

Symposium
Improved outcome by smarter use of radiotherapy .................................................... Abs. 463-465
Quantitative Imaging for Radiation Oncology ............................................................ Abs. 466-468
Advanced methods to account for proton range uncertainties in treatment planning ........ Abs. 469-472
Care, communication and new technology in brain radiotherapy ............................. Abs. 473-475

Poster Viewing
Poster viewing 9: Applied dosimetry ............................................................................ Abs. 476-484

Joint Symposium
ESTRO-IAEA: The role of hypofractionation in current radiotherapy and its impact in planning radiotherapy services ............................ Abs. 485-488

Debate
Which is the best technique for the delivery of APBI? ................................................ Abs. 489-492

Proffered Papers
Biomarkers and bioimaging in radiotherapy ............................................................... Abs. 493-499
CL 9: Proffered papers: Late breaking abstracts ......................................................... Abs. 500-505
CL 10: Proffered papers: Pelvic Tumours ................................................................ Abs. 506-512
PH 9: Proffered paper: Artificial intelligence and novel imaging approaches ............ Abs. 513-519
PH 10: Proffered paper: Treatment planning innovations ........................................ Abs. 520-526
RTT 5: Improving accuracy in patient positioning ................................................................. Abs. 527-532

Poster Viewing
Poster viewing 10: Radiobiology .......................................................................................... Abs. 533-541

Award Lecture
Klaus Breur Award Lecture ................................................................................................. Abs. 542
Academic award: Jack Fowler University of Wisconsin Award ........................................... Abs. 543
Company Award Lectures .................................................................................................. Abs. 544

Symposium
Adaptive RT: reactive or proactive? .................................................................................... Abs. 545-548
Predictive models of toxicity and big data, big open issues .............................................. Abs. 549-552
Biological Imaging for Radiotherapy .................................................................................. Abs. 553-556
New developments for breast cancer irradiation .............................................................. Abs. 557-560

Joint Symposium
ESTRO-EORTC: Moving radiation oncology forward to improve patient outcomes ................ Abs. 561-563

Debate
In 10 years physicists will need different training to include more …

Proffered Papers
PH 11: Proffered paper: Proton range and dose verification ........................................... Abs. 564-570

Symposium
Education and Advance Practice ...................................................................................... Abs. 571-573

Poster Viewing
Poster viewing 11: Novel strategies in IGRT ....................................................................... Abs. 574-581

Multidisciplinary Tumour Board
Bladder cancer

Debate
Can early-regression-guided adaptive RT eRG-ART improve the pathological response in neo-adjuvant treatments?

Symposium
Recent insights into adverse cardiac effects from multimodal radiation therapy ............. Abs. 582-585

Proffered Papers
RB 6: Pre-clinical research in particle therapy ................................................................. Abs. 586-590
CL 11: Proffered papers: Breast ....................................................................................... Abs. 591-596
CL 12: Proffered papers: Health Economics and Health services research .................... Abs. 597-602
PH 12: Proffered paper: Multi centre analysis of quality ............................................... Abs. 603-609
PH 13: Proffered paper: Modelling toxicity .................................................................... Abs. 610-616
RTT 6: Education and quality management for optimising patient care ......................... Abs. 617-621

Poster Viewing
Poster viewing 12: GI and Urological Cancers ................................................................. Abs. 622-629

Award Lecture
Donald Hollywood award lecture ...................................................................................... Abs. 631
Highlights of proffered papers ........................................................................................ Abs. 632-635

30 APRIL 2019

Teaching Lecture
The DNA damage response to radiotherapy: mechanisms and therapeutic opportunities .................................................... Abs. 636
Are adolescents and young adults AYA a specific patients' population? ................................................................. Abs. 637
Hypofractionation; Is there rationale from biology a/b ratio? ......................................................................................... Abs. 638
Recent insights into radiotherapy tolerance from the REQUITE Consortium ................................................................. Abs. 639
Integration of PET imaging in radiation treatment planning .......................................................................................... Abs. 640
Implementation and practice of SRS and SBRT: Consensus guidelines and protocols ..................................................... Abs. 641
How to select patients for radiotherapy with protons instead of photons ................................................................. Abs. 642
MR-guided radiotherapy in the pelvic region .................................................................................................................... Abs. 643

Symposium
Radiotherapy biomarkers: a confluence of imaging, genetics and pathology ................................................................. Abs. 644-647
Palliation in RT - How much is enough? ........................................................................................................................ Abs. 648-651
Mechanisms of treatment resistance in glioma .............................................................................................................. Abs. 652-655

Debate
This house believes that there is still a role for radiotherapy in pancreatic cancer .................................................. Abs. 656-659

Symposium
New developments in Head and Neck Cancer treatment .............................................................................................. Abs. 660-662
New detector developments ........................................................................................................................................ Abs. 663-666

Proffered Papers
PH 14: Proffered paper: Treatment planning of proton therapy ....................................................................................... Abs. 667-673

Symposium
Focus on the Pelvic Region ........................................................................................................................................ Abs. 674-676

Joint Symposium
ESTRO-RANZCR: Radiotherapeutical management of oligometastatic disease .......................................................... Abs. 677-680

Symposium
Plan of the day - present status and future aims ........................................................................................................ Abs. 681-684

Debate
This house believes that immunotherapy is really changing radiation oncology ............................................................ Abs. 685-688
This house believes that patients with squamous cell cancer of the esophagus no longer need surgery ................................ Abs. 689-692

Symposium
Controversies in the management of brain metastases ................................................................................................. Abs. 693-696
Improving delineation in RT: not only for the doctor ................................................................................................. Abs. 697-700
A new era for radiotherapy anthropomorphic phantoms ............................................................................................ Abs. 701-704

Debate
Workload/clinic logistics, and not technical uncertainties, are the main barrier to widespread implementation  
of adaptive RT practice ................................................................................................................................ Abs. 705-706

Closing debate
Data mining or data farming? ................................................................................................................................ Abs. 707-708

POSTER
Clinical track: Head and Neck ................................................................................................................................ Abs. 709-733
Clinical track: CNS .............................................................................................................................................. Abs. 734-757
Clinical track: Haematology ................................................................................................................................ Abs. 758
Clinical track: Breast .............................................................................................................................................. Abs. 759-767
Clinical track: Lung .............................................................................................................................................. Abs. 768-785
Clinical track: Upper GI oesophagus, stomach, pancreas, liver .................................................................................. Abs. 786-813
Clinical track: Lower GI colon, rectum, anus ................................................................................................................ Abs. 814-821
Clinical track: Gynaecological endometrium, cervix, vagina, vulva .......................................................................... Abs. 822-833
Clinical track: Prostate .......................................................................................................................................... Abs. 834-862
Clinical track: Urology-non-prostate ........................................................................................................................ Abs. 863-864
Clinical track: Skin cancer / malignant melanoma ......................................................... Abs. 1609-1614
Clinical track: Paediatric tumours ................................................................................ Abs. 1600-1608
Clinical track: Palliation ............................................................................................... Abs. 1593-1596
Clinical track: Elderly ................................................................................................ Abs. 1585-1587
Clinical track: Other .................................................................................................. Abs. 1579-1583

Physics track: Basic dosimetry and phantom and detector development .................. Abs. 891-898
Physics track: Dose measurement and dose calculation .............................................. Abs. 899-911
Physics track: Radiation protection, secondary tumour induction and low dose ....... Abs. 912-914
Physics track: Treatment plan optimisation: algorithms .............................................. Abs. 915-919
Physics track: Treatment planning: applications ....................................................... Abs. 920-946
Physics track: Radiobiological and predictive modelling, and radiomics ............... Abs. 947-969
Physics track: Intra-fraction motion management ...................................................... Abs. 970-979
Physics track: Adaptive radiotherapy and inter-fraction motion management ........ Abs. 980-998
Physics track: Quantitative functional and biological imaging ................................ Abs. 999-1000
Physics track: Imaging acquisition and processing .................................................... Abs. 1001-1012
Physics track: Implementation of new technology, techniques, clinical protocols or trials including QA & audit ....................... Abs. 1013-1039

Brachytherapy: Breast ................................................................................................. Abs. 1040
Brachytherapy: Gynaecology .................................................................................... Abs. 1041-1043
Brachytherapy: Head and neck ................................................................................ Abs. 1044-1045
Brachytherapy: Physics .............................................................................................. Abs. 1046-1052
Brachytherapy: Prostate ............................................................................................ Abs. 1053-1059
Brachytherapy: Miscellaneous ................................................................................... Abs. 1060-1064

Radiobiology track: Radiobiology of normal tissues ................................................. Abs. 1065
Radiobiology track: Radiobiology of stem cells cancer and normal tissue ............. Abs. 1066-1067
Radiobiology track: Radiobiology of particles and heavy ions ................................. Abs. 1068-1069
Radiobiology track: Radiation-induced signalling pathways .................................... Abs. 1070-1071
Radiobiology track: Immuno-radiobiology ............................................................... Abs. 1072-1074
Radiobiology track: Radiation and tumour metabolism .......................................... Abs. 1075-1079
Radiobiology track: DNA damage response ............................................................ Abs. 1080-1085
Radiobiology track: Biological therapies e.g. viruses, vaccines ............................. Abs. 1086
Radiobiology track: Radiation response biomarkers ............................................... Abs. 1087-1090

RTT track: Patient preparation, positioning and immobilisation .............................. Abs. 1091-1095
RTT track: Imaging acquisition and registration, OAR and target definition .......... Abs. 1096-1105
RTT track: Treatment planning and dose calculation / QC and QA ......................... Abs. 1106-1111
RTT track: Image guided radiotherapy and verification protocols ......................... Abs. 1112-1116
RTT track: Motion management and adaptive strategies ......................................... Abs. 1117-1121
RTT track: Patient care, side effects and communication ..................................... Abs. 1122-1125
RTT track: Education and training/role development ............................................. Abs. 1126-1130
RTT track: Risk management/quality management ................................................ Abs. 1131-1132

ELECTRONIC POSTER
Clinical track: Head and Neck .................................................................................. Abs. 1133-1205
Clinical track: CNS ................................................................................................... Abs. 1206-1263
Clinical track: Haematology ...................................................................................... Abs. 1264-1268
Clinical track: Breast ............................................................................................... Abs. 1269-1333
Clinical track: Lung ................................................................................................ Abs. 1334-1391
Clinical track: Upper GI oesophagus, stomach, pancreas, liver .............................. Abs. 1392-1445
Clinical track: Lower GI colon, rectum, anus .......................................................... Abs. 1446-1474
Clinical track: Gynaecological endometrium, cervix,vagina,vulva ......................... Abs. 1475-1511
Clinical track: Prostate ........................................................................................... Abs. 1512-1584
Clinical track: Urology-non-prostate .................................................................... Abs. 1585-1592
Clinical track: Skin cancer / malignant melanoma ................................................ Abs. 1593-1600
Clinical track: Sarcoma ........................................................................................... Abs. 1601-1608
Clinical track: Paediatric tumours .......................................................................... Abs. 1609-1614